Gemcitabine in the treatment of epithelial ovarian cancer;La gemcitabine dans le traitement du cancer épithélial de I'ovaire

Bulletin du Cancer

Volumn 89, Issue SPEC. ISS., 2002, Pages

  Pautier, Patricia ^a   Gutierrez, Maya ^a   Lhomme, Catherine ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Gemcitabine; Ovarian cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; NAVELBINE; OXALIPLATIN; PACLITAXEL; TOPOTECAN;

ALOPECIA; ANEMIA; CANCER REGRESSION; CANCER RESISTANCE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HUMAN; LEUKOPENIA; NAUSEA; NEUTROPENIA; OVARY CANCER; RECURRENT CANCER; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMATOLOGIC DISEASES; HUMANS; MULTICENTER STUDIES; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PACLITAXEL; PALLIATIVE CARE; PRODRUGS; REMISSION INDUCTION; TOPOTECAN; TREATMENT OUTCOME; VINBLASTINE;

EID: 0036696023     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 malor cancers in 1990. Int J Cancer 1999; 80: 724-841.
2. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
3. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000; 92: 699-708.
4. Cannistra SA. Cancer of the ovary. N Engl J Med 1993; 329: 1550-9.
5. Markman M. Prognostic factors in salvage therapy of ovarian cancer. Ann Oncol 1997; 8: 963-8.
6. Sabbatini P, Spriggs D. Salvage therapy for ovarian cancer. Oncology (Huntingt) 1998; 12: 833-43; discussion 844-846, 848, 851.
7. Ozols RF. The current role of gemcitabine in ovarian cancer. Sem Oncol 2001; 28 (suppl. 17): 18-24.
8. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990; 50: 4417-22.
9. Lund B, Kristjansen PE, Hansen HH. Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 1993; 19: 45-55.
10. Ruiz van Haperen VW, Veerman G, Eriksson S, Stegmann AP, Peters GJ. Induction of resistance to 2′,2′-difluorodeoxycytidine in the human ovarian cancer cell line A2780. Semin Oncol 1995; 22 (suppl. 11): 35-41.
11. Lund B, Paaske H, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86: 1530-2.
12. Von Minckwitz G, Bauknecht T, Visseren-Grul CM, Neijt JP. Phase II study of GEMZAR in ovarian cancer. Ann Oncol 1999; 10: 853-5.
13. Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA, et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996; 63: 89-93.
14. Kudelka AP, Verschraegen C, Edwards CL, Freedman RS, Plunkert WK, Nicol S, et al. A preliminary report of a phase 2 study of gemcitabine in women with platinum refractory mullerian (ovarian, fallopian tube and primary peritoneal) carcinomas. Proc Am Soc Clin Oncol 1999; 18 (abstr. 1457).
15. Coenen M, Berteloot P, Amant F, Vangramberen M, Vergote I. Gemcitabine in platin-paclitaxel resistant ovarian cancer. Proc Am Soc Clin Oncol 2000; 19 (abstr. 1603).
16. Underhill C, Parnis FX, Highley M. A phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer (EOC). Ann Oncol 1996; 7 (suppl. 5) (abstr. 3240).
17. Bergman AM, Ruiz van Haperen VWT, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996; 2: 521-30.
18. Faivre S, Raymond E, Woynarowski JM, Cvitkovic E. Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999; 44: 117-23.
19. Krakowski I, Petit T, Kayitalire L, Weber B, Beaudoin M, Canon JL, et al. Gemzar in combination with cisplatin in advanced ovarian cancer: a phase II study. Proc Am Soc Clin Oncol 1998; 17 (abstr. 1373).
20. Nogue M, Cicera L, Arcusa M, Tusquets I, Batiste-Alentorn E, Font A, et al. Gemzar combined with cisplatin first line: a phase II study in patients with advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol 1998; 17 (abstr. 1377).
21. Bauknecht T, Grieshaber Ch, Breitbach GP, Villena-Heinsen C, Wallwiener D, Morack G, et al. Gemcitabine (GEM) in combination with cisplatin (CIS) in previously untreated patients ≥ 60 years with FIGO stage IIIc or IV epithelial ovarian cancer: a phase II study preliminary results. Proc Am Soc Clin Oncol 1999; 18 (abstr. 1376).
22. Hansen SW, Anderson H, Boman K, Hansen M, Havsteen H, Rosenberg P, et al. Gemcitabine, carboplatin, and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB-IV. Proc Am Soc Clin Oncol 1999; 18 (abstr. 1379).
23. Kunkel LM, Evans SS, Dottino PR, DiSaia PJ, Nagourney RA. Cisplatin (CDDP) and gemcitabine (DFDC) in relapsed ovarian cancer. Proc Am Soc Clin Oncol 1998; 17 (abstr. 1379).
24. Geersten P, Hansen M, Stroyer I, Hansen SW. Combination chemotherapy with platinum, paclitaxel and gemcitabine in patients with relapsed ovarian carcinoma. Proc Am Soc Clin Oncol 1999; 18 (abstr. 1395).
25. Orlando M, Nadal J, Chacon RD. Gemcitabine (G) and carboplatine (C) in patients (pts) with relapsed ovarian cancer (ROC): a phase I-II study. Proc Am Soc Clin Oncol 2000; 19 (abstr. 1594).
26. Faivre S, Raymond E, Lokiec F, Monnerat C, Vicente-Azevedo J, Pautier P, et al. Results of the phase I-II study of gemcitabine (GEM) in combination with oxaliplatin (OX) in patients (pts) with advanced non-small-cell lung cancer (NSCLC) and ovarian cancer (OC). Proc 25th ESMO 2000 (abstr. 646).
27. Pignata S, Varriale E, Casella G, Iodice F, De Placido G, Perrrone F, et al. Phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancer. Ann Oncol 2000; 11: 613-6.
28. Tobias DH, Runowicz C, Mandeli J, Muggia F, Astrow A, Cohen C, et al. A phase I trial of gemcitabine and doxil for recurrent epithelial ovarian cancer. Proc Am Soc Clin Oncol 2000; 19 (abstr. 1551).
29. Poole CJ, Perren T, Hogberg T, Cook J, Jenkins AH, Ridderheim M, et al. Phase I study to investigate the optimal dose and schedule of gemcitabine (G) and paclitaxel (P) in combination in patients with previously treated epithelial ovarian cancer. Proc Am Soc Clin Oncol 1998; 17 (abstr. 1380).
30. Roman L, Garcia AA, Facio G, Jeffers S, Santiago J, Muderspach L, et al. Phase II study of weekly paclitaxel and gemcitabine in platinum resistant ovarian cancer. Proc Am Soc Clin Oncol 2001; 20 (abstr. 877).
31. Sehouli J, Lichtenegger W, Hindenburg H, Klare P, Keil E, Heinrich G, et al. A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with platinum and paclitaxel. Proc Am Soc Clin Oncol 2001; 20 (abstr. 861).
32. Lentz SE, Garcia AA, Bookman M, Mutch D, Rodriguez L, Look KY. Phase I trial of gemcitabine and protracted oral etoposide in recurrent gynecological tumors: a gynecologic oncology group study. Proc Am Soc Clin Oncol 2000; 19 (abstr. 1604).
33. Spanu P, Ferrero A, Fuso L, Ponzonz R, Magistris A, Jacomuzzi E, et al. Gemcitabine and vinorelbine in relapsed epithelial ovarian cancer: a phase II study. Proc Am Soc Clin Oncol 2001; 20 (abstr. 848).